The insulin-like growth factor 1(bIGF-1) induced IGF-1R and AKT phosphorylation, suggesting that it may become a potential clinical therapeutic agent for the treatment of human lung cancer (Zhang J. et al., 2018). Here, AKT1 is linked to lung carcinoma.